Patent SG-11201805048S-A (SG)
Title: Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia
Inventor: BROWNSTEIN CARRIE
IPC: A61K39/00
Filed: 2016-12-21
Abstract: 5 0 5 10 50 n W O 20 171127 / 6 2 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/112762 Al 29 June 2017 (29.06.2017) WIPO I PCT 1111111111111101110111111111110101111101110111011101011111111011111111111110111111 Treatment in NSG mice with established Raji tumors Tum or Vo lume mm ( 3) 150 (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2016/068003 (22) International Filing Date: 21 December 2016 (21.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/270,749 22 December 2015 (22.12.2015) US 62/306,031 9 March 2016 (09.03.2016) US (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (US). (72) Inventor: BROWNSTEIN, Carrie; c/o Regeneron Phar- maceuticals, Inc., 777 Old Saw Mill River Road, Tarry- town, New York 10591-6707 (US). (74) Agents: TERMES, Lance, A. et al.; Schwabe, Williamson & Wyatt, 1211 SW 5th Avenue, Suite 1900, Portland, OR 97204 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, [Continued on next page] (54) Title: BISPECIFIC ANTI-CD20/ANTI-CD3 ANTIBODIES TO TREAT ACUTE LYMPHOBLASTIC LEUKEMIA (57) : The present invention provides methods for treating, reducing the severity, or inhibiting the growth of acute lymphoblastic leukemia. The methods of the present invention comprise administer- ing to a subject in need thereof a thera- 1000 peutically effective amount of a bispecific antibody that specifically binds to CD20 and CD3. Days Post Treatment Control-Vehicle -NI- Control Ab 6 - 0.4 m gAcg ; 2x/week -le- Ab 1 -OA mg/kg ; 2x/week -- Rituximab -8 mg/kg; 5xlweek -4- C D19xCD3 BiTE - 0.5 mgkg; 5x/week compared to vehicle commit 41.;;;- competed to Ab 6 control; @ - compared to rin.Lximab; ns - not significant Data represents the composite data from n=4-6 mice per grow. Data are expressed as mean (SEM) and were analysed using analysis of variance (ANOVA) and post hoc tests to probe significant effects (Tukey's for two-way ANOVA). Two mice in the CD19 BITE group, and one mouse from the Ab 1 gimp was excluded from this composite graph due to early death in order to analyze data by two-way ANOVA. Figure 1 WO 2017/112762 Al 1#11101M011111 1111111101011111301011010111111111101111111011110111111 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Published: GW, KM, ML, MR, NE, SN, TD, TG). with international search report (Art. 21(3)) Declarations under Rule 4.17: with sequence listing part of description (Rule 5.2(a)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))